Ablynx Release: Publication in Accordance With the Act of 2 May 2007 Regarding the Publication of Major Shareholdings

GHENT, BELGIUM--(Marketwire - September 12, 2008) - Ablynx (Euronext Brussels: ABLX), a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, published today the information in accordance with Articles 15, 18 and 29 of the Belgian Act of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Act").